Literature DB >> 8096166

Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry.

M Wakasugi1, R Wakao, M Tawata, N Gan, K Koizumi, T Onaya.   

Abstract

OBJECTIVE: We assessed the changes of bone mass in patients with hyperthyroidism by measuring bone mineral density using a new method, dual energy X-ray absorptiometry.
DESIGN: The values of bone mineral density in patients with hyperthyroidism were compared with data obtained from the controls, and we assessed the correlation analysis between bone mineral density and several metabolic parameters. PATIENTS: We studied 52 Japanese patients with hyperthyroidism (20 males, 32 females). Healthy normal subjects served to establish the mean bone mineral density in the healthy Japanese population (Shiraki et al. 1991). MEASUREMENT: Bone mineral density was assessed by the measurement of lumbar vertebrae and femur by dual energy X-ray absorptiometry. The bone mineral density of vertebrae for each patient was calculated as the percentage of the mean value (% bone mineral density) obtained from an age and sex-matched control group. Blood was drawn to measure the levels of serum calcium, phosphorus, creatinine, alkaline phosphatase, free T3, free T4, TSH, TSH receptor antibody, parathyroid hormone, and serum osteocalcin.
RESULTS: The percentage bone mineral density of vertebrae in patients was 92.6 as compared with that of normal controls, and was inversely correlated with serum TSH receptor antibody, osteocalcin, and alkaline phosphatase.
CONCLUSIONS: These findings suggest that bone mineral density is decreased in patients with hyperthyroidism and that TSH receptor antibody, osteocalcin, and alkaline phosphatase are sensitive markers of bone metabolism alterations in hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096166     DOI: 10.1111/j.1365-2265.1993.tb01007.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.

Authors:  T Majima; Y Komatsu; K Doi; C Takagi; M Shigemoto; A Fukao; T Morimoto; J Corners; K Nakao
Journal:  Osteoporos Int       Date:  2006-04-07       Impact factor: 4.507

2.  A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.

Authors:  M T McDermott; J J Perloff; G S Kidd
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

3.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

4.  Wnt Inhibitors and Bone Mineral Density in Patients with Graves' Disease Treated with Antithyroid Drugs: A Preliminary Prospective Study.

Authors:  Dunja Mudri; Tomislav Kizivat; Ivica Mihaljević; Ines Bilić Ćurčić
Journal:  Metabolites       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.